Demographic and Survivorship Disparities in Non–muscle-invasive Bladder Cancer in the United States
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: To examine survivorship disparities in demographic factors and risk status for non–muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. Methods: We used the US National Cancer Institute’s Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan- Meier (K-M) and Cox proportional hazard methods for survival analysis. Results: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. Conclusions: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients.
Abstract
Objectives: To examine survivorship disparities in demographic factors and risk status for non–muscle-invasive bladder cancer (NMIBC), which accounts for more than 75% of all urinary bladder cancers, but is highly curable with early identification and treatment. Methods: We used the US National Cancer Institute’s Surveillance, Epidemiology, and End Results registries over a 19-year period (1988-2006) to examine survivorship disparities in age, sex, race/ethnicity, and marital status of patients and risk status classified by histologic grade, stage, size of tumor, and number of multiple primary tumors among NMIBC patients (n=29 326). We applied Kaplan- Meier (K-M) and Cox proportional hazard methods for survival analysis. Results: Among all urinary bladder cancer patients, the majority of NMIBCs were in male (74.1%), non-Latino white (86.7%), married (67.8%), and low-risk (37.6%) to intermediate-risk (44.8%) patients. The mean age was 68 years. Survivorship (in median life years) was highest for non-Latino white (5.4 years), married (5.4 years), and low-risk (5.7 years) patients (K-M analysis, p<0.001). We found significantly lower survivorship for elderly, male (female hazard ratio [HR], 0.96), Latino (HR, 1.20), and unmarried (married HR, 0.93) patients. Conclusions: Survivorship disparities were ubiquitous across age, sex, race/ethnicity, and marital status groups. Non-white, unmarried, and elderly patients had significantly shorter survivorship. The implications of these findings include the need for a heightened focus on health policy and more organized efforts to improve access to care in order to increase the chances of survival for all patients.
참고문헌 (18)
- Anastasiadis A, "Best practice in the treatment of nonmuscle invasive bladder cancer", Ther Adv Urol, 4(1), pp.13~32 (2012)[DOI]
- "Cancer stat facts: bladder cancer"[URL]
- "Survival rates for bladder cancer"[URL]
- Cheng L, "Histologic grading of urothelial carcinoma: a reappraisal", Hum Pathol, 43(12), pp.2097~2108 (2012)[DOI]
- MacLennan GT, "Histologic grading of noninvasive papillary urothelial neoplasms", Eur Urol, 51(4), pp.889~897 (2007)[DOI]
- Kirkali Z, "Bladder cancer: epidemiology, staging and grading, and diagnosis", Urology, 66(6 Suppl 1), pp.4~34 (2005)
- Babjuk M, "EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013", Eur Urol, 64(4), pp.639~653 (2013)[DOI]
- Bobinski J, "EORTC risk tables--a new diagnostic tool in urology", Pol Merkur Lekarski, 27(162), pp.524~528 (2009)
- Barton MK, "High morbidity and mortality found for high-risk, non-muscle-invasive bladder cancer", CA Cancer J Clin, 63(6), pp.371~372 (2013)[DOI]
- Snyder C, "Patterns of care for the treatment of bladder cancer", J Urol, 169(5), pp.1697~1701 (2003)[DOI]
- Hollenbeck BK, "Racial differences in treatment and outcomes among patients with early stage bladder cancer", Cancer, 116(1), pp.50~56 (2010)
- Underwood W 3rd, "Gender and geographic influence on the racial disparity in bladder cancer mortality in the US", J Am Coll Surg, 202(2), pp.284~290 (2006)[DOI]
- 서경원, "The Efficacy of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer after Intravesical Bacillus Calmette-Guerin Instillation", Investigative and Clinical Urology, 51(3), pp.165~170 (2010), 대한비뇨의학회
- Millan-Rodriguez F, "Multivariate analysis of the prognostic factors of primary superficial bladder cancer", J Urol, 163(1), pp.73~78 (2000)[DOI]
- "Number of persons by race and Hispanic ethnicity for SEER participants (2010 census data 1)"[URL]
- National Cancer Institute, "SEER program coding and staging manual 2016" (2016)
- "Site recode ICD-O-3 (1/27/2003) definition"[URL]
- "AJCC cancer staging"[URL]